Sunitinib treatment increases the antitumor immunity response in a phase III trial, where a higher PD-L1 level and a lower p62 level were observed in the tumor region of anti-PD-1-treated responder NSCLC patients compared to non-responder patients. The gene discussed is PDCD1; the disease is neoplasm.